A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Telatinib, a Selective Inhibitor of the Vascular Endothelial Growth Factor (VEGF) Receptor, in Adult Chinese Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2017
At a glance
- Drugs Telatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eddingpharm
- 28 Nov 2017 Status changed from not yet recruiting to recruiting.
- 01 Jun 2017 Status changed from planning to not yet recruiting.
- 17 Jan 2014 New trial record